EMA/649948/2010

European Medicines Agency decision

P/226/2010

of 27 October 2010

on the agreement of a paediatric investigation plan and on the granting of a waiver for atazanavir sulphate (Reyataz), (EMA-000804-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8670
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/226/2010

of 27 October 2010

on the agreement of a paediatric investigation plan and on the granting of a waiver for atazanavir sulphate (Reyataz), (EMA-000804-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Bristol-Myers Squibb Pharma EEIG on 8 January 2010 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 8 October 2010, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for atazanavir sulphate (Reyataz), capsule, hard, oral powder, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for atazanavir sulphate (Reyataz), capsule, hard, oral powder, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Bristol-Myers Squibb Pharma EEIG, Uxbridge Bussiness Park, Sanderson Road, UB8 1 DH Uxbridge, United Kingdom.

Done at London, 27 October 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

EMA/PDCO/531037/2010

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver

EMA-000804-PIP01-09

Scope of the application

Active substance(s):

Atazanavir sulphate

Invented name:

Reyataz

Condition(s):

Treatment of human immunodeficiency virus (HIV-1) infection

Authorised indication(s): see Annex II

Pharmaceutical form(s):

Capsule, hard
Oral powder

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Bristol-Myers Squibb Pharma EEIG

Information about the authorised medicinal product: see Annex II

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Bristol-Myers Squibb Pharma EEIG submitted for agreement to the European Medicines Agency on 8 January 2010 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 18 February 2010.

Supplementary information was provided by the applicant on 30 July 2010 and 23 September 2010.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with

     Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population

     Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Icelandic and the Norwegian Paediatric Committee member(s) agree(s) with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 8 October 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan.

1. Waiver

1.1. Condition: Treatment of human immunodeficiency virus (HIV-1) infection

The waiver applies to:

- oral powder, oral use,
- the paediatric population from birth to less than 3 months,
- on the grounds that the specific medicinal product is likely to be unsafe.

And to:

- the paediatric population from 8 years to less than 18 years,
- on the grounds that the specific medicinal product is likely to be ineffective.

The waiver applies to:

- capsules, hard oral use,
- the paediatric population from birth to less than 6 years,
- on the grounds that the specific medicinal product is likely to be unsafe.

And to:

- the paediatric population from 6 years to less than 18 years,
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as the needs are already covered.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of human immunodeficiency virus (HIV-1) infection

2.1.1. Indication(s) targeted by the PIP

Treatment of human immunodeficiency virus (HIV-1) infection

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 months to less than 8 years of age.

2.1.3. Pharmaceutical form(s)

Oral powder (50 mg/sachet)

2.1.4. Studies

Area	Number of studies	Description
Quality	1	Development of the oral powder (50 mg/sachet)
Non-clinical	0	Not applicable.
Clinical	2	Study 1: Single arm, open-label, multicentre study to evaluate the safety, efficacy and pharmacokinetics of atazanavir powder boosted with ritonavir with an optimised nucleoside reverse transcriptase inhibitor background therapy, in HIV infected paediatric patients from 3 months to less than 6 years of age. Study 2: Single arm, open-label, multicentre study to evaluate the safety, efficacy and pharmacokinetics of atazanavir powder boosted with ritonavir with an optimised nucleoside reverse transcriptase inhibitor background therapy, in HIV infected, antiretroviral naïve and experienced paediatric patients from 3 months to less than 8 years of age.

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By October 2013
Deferral for one or more studies contained in the paediatric investigation plan:	No

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s)

1. Treatment of HIV-1 infection

REYATAZ capsules, co-administered with low dose ritonavir, are indicated for the treatment of HIV-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products.

Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations). There are very limited data available from children aged 6 to less than 18 years (see sections 4.4 and 5.1).

The choice of REYATAZ in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient's treatment history (see sections 4.4 and 5.1).

Oral powder

REYATAZ is indicated for the treatment of HIV-1 infected adults in combination with other antiretroviral medicinal products.

In antiretroviral treatment experienced patients, the demonstration of efficacy is based on a study comparing REYATAZ 300 mg once daily in combination with ritonavir 100 mg once daily with lopinavir/ritonavir, each regimen in combination with tenofovir (see sections 4.8 and 5.1). Based on available virological and clinical data, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations). The choice of REYATAZ in treatment experienced patients should be based on individual viral resistance testing and the patient's treatment history (see section 5.1).

EU Number	**(Invented) name**	**Strength**	**Pharmaceutical Form**	**Route of Administration**	**Packaging**	**Package size**
EU/1/03/267/001	Reyataz	100 mg	Capsule, hard	Oral use	bottle (HDPE)	60 capsules
EU/1/03/267/002	Reyataz	100 mg	Capsule, hard	Oral use	blister (alu/alu)	60 capsules
EU/1/03/267/003	Reyataz	150 mg	Capsule, hard	Oral use	bottle (HDPE)	60 capsules
EU/1/03/267/004	Reyataz	150 mg	Capsule, hard	Oral use	blister (alu/alu)	60 capsules
EU/1/03/267/005	Reyataz	200 mg	Capsule, hard	Oral use	bottle (HDPE)	60 capsules
EU/1/03/267/006	Reyataz	200 mg	Capsule, hard	Oral use	blister (alu/alu)	60 capsules
EU/1/03/267/008	Reyataz	300 mg	Capsule, hard	Oral use	bottle (HDPE)	30 capsules
EU/1/03/267/009	Reyataz	300 mg	Capsule, hard	Oral use	blister (alu/alu)	30 capsules
EU/1/03/267/010	Reyataz	300 mg	Capsule, hard	Oral use	bottle (HDPE)	30 capsules